660 Hits in 1.8 sec

Can We Escape Stroke and Alzheimer Disease?

T. Kurth, G. Logroscino
2006 Stroke  
doi:10.1161/01.str.0000199626.23374.e4 pmid:16397177 fatcat:3y42i636nffq3djcq33vgyzesi

The Metabolic Syndrome: More Than the Sum of Its Components?

T. Kurth, G. Logroscino
2008 Stroke  
Editorial by guest on April 8, 2017 Downloaded from 14. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928 -935. 15. Cook NR. Statistical evaluation of prognostic vs diagnostic models: beyond the ROC curve. Clin Chem. 2008;54:17-23.
doi:10.1161/strokeaha.107.505073 pmid:18323482 fatcat:7hg6kfpp5fh3tbamvhsdgstodq

Low Incidence of Stroke in Southern Italy: A Population-Based Study

G. Manobianca, S. Zoccolella, A. Petruzzellis, A. Miccoli, G. Logroscino
2008 Stroke  
Key Words: stroke Ⅲ incidence Ⅲ registry Ⅲ stroke unit Ⅲ population-based Ⅲ Italy Ⅲ Mediterranean area G eographical variations in the incidence of stroke may be related to differences in the prevalence  ... 
doi:10.1161/strokeaha.108.519421 pmid:18703805 fatcat:256fgwya7ndonio6zghfvpclze

Migraine frequency and risk of cardiovascular disease in women

T. Kurth, M. Schurks, G. Logroscino, J. E. Buring
2009 Neurology  
Migraine has been associated with risk of cardiovascular disease (CVD). Data on the association between migraine frequency and CVD are sparse. Methods: Prospective cohort study of 27,798 US women aged Ն45 years, who were free of CVD, and for whom we had information on lipids and migraine frequency. We categorized migraine frequency as Ͻ monthly, monthly, and Ն weekly. Incident CVD was confirmed after medical record review. Results: Of the 3,568 women with active migraine at baseline, 75.3%
more » ... ted a migraine frequency of Ͻ monthly, 19.7% monthly, and 5.0% Ն weekly. During 11.9 years of follow-up, 706 CVD events occurred. Compared with women without migraine, the multivariable-adjusted hazard ratios (HRs) (95% confidence intervals) among active migraineurs for CVD were 1.55 (1.22-1.97), 0.65 (0.31-1.38), and 1.93 (0.86 -4.33) for an attack frequency of Ͻ monthly, monthly, and Ն weekly, respectively. The association between migraine frequency and CVD was only apparent among migraineurs with aura. Among those, the multivariable-adjusted HRs for women with a migraine frequency Ͻ monthly ranged from 1.81 (1.30 -2.50) for coronary revascularizations to 2.43 (1.58 -3.74) for myocardial infarction. For women with active migraine with aura and migraine frequencies of Ն weekly, we only found significant increased risk of ischemic stroke (HR ϭ 4.25 [1.36 -13.29]). Conclusions: In our data, the association between migraine and cardiovascular disease varies by migraine frequency. Significant associations were only found among women with migraine with aura. Ischemic stroke was the only outcome associated with a high-attack frequency while a low-attack frequency was associated with any vascular event. Low number of outcome events should caution the interpretation. Neurology ® 2009;73:581-588 GLOSSARY CI ϭ confidence interval; CVD ϭ cardiovascular disease; HR ϭ hazard ratio; MI ϭ myocardial infarction; WHS ϭ Women's Health Study.
doi:10.1212/wnl.0b013e3181ab2c20 pmid:19553594 pmcid:PMC2731618 fatcat:gmehiuohw5chdf7iogqn5jlal4

Smoking, Parkinson's Disease, and Melanoma

J. A. Driver, G. Logroscino, J. E. Buring, J. M. Gaziano, T. Kurth
2007 Cancer Epidemiology, Biomarkers and Prevention  
Driver Giancarlo Logroscino Julie E. Buring J. Michael Gaziano Tobias Kurth Divisions of Aging and Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts  ... 
doi:10.1158/1055-9965.epi-07-2666 fatcat:6b7mcd3x7rarjpmm6dxqj3jsoi

The familiarity of idiopathic scoliosis: statistical analysis and clinical considerations

A. G. Aulisa, V. Guzzanti, M. Galli, G. Bottaro, O. Vitelli, P. Ferrara, G. Logroscino
2012 European Journal of Orthopaedic Surgery & Traumatology  
doi:10.1007/s00590-012-1060-6 pmid:23412192 fatcat:cegowtlyeffutjimtzcmgbiwzy

Primary Prevention of Stroke by Healthy Lifestyle

S. E. Chiuve, K. M. Rexrode, D. Spiegelman, G. Logroscino, J. E. Manson, E. B. Rimm
2008 Circulation  
We defined a low-risk lifestyle as not smoking, a body mass index Ͻ25 kg/m 2 , Ն30 min/d of moderate activity, modest alcohol consumption (men, 5 to 30 g/d; women, 5 to 15 g/d), and scoring within the  ...  d among women and 5 to 30 g/d among men.  ...  We defined moderate alcohol consumption as at least 5 g/d, with an upper limit of 15 g/d for women and 30 g/d for men, consistent with guidelines for moderate alcohol intake in the United States. 21  ... 
doi:10.1161/circulationaha.108.781062 pmid:18697819 pmcid:PMC2730914 fatcat:qx3gta52kffdhfucofbwhlsosy

Mediterranean Diet in Predementia and Dementia Syndromes

V. Solfrizzi, V. Frisardi, D. Seripa, G. Logroscino, B. P. Imbimbo, G. D'Onofrio, F. Addante, D. Sancarlo, L. Cascavilla, A. Pilotto, F. Panza
2011 Current Alzheimer Research  
In fact, in several cross-sectional studies, moderate drinking, from up to 1 drink per day (up to 14 g of alcohol) to 4 drinks per day (52 g of alcohol), as compared with nondrinking has been associated  ... 
doi:10.2174/156720511796391809 pmid:21605047 fatcat:v7wmnwiqi5d7zhkm3ojk5kzd24

Estimating risk for developing epilepsy: A population-based study in Rochester, Minnesota

D. C. Hesdorffer, G. Logroscino, E. K. T. Benn, N. Katri, G. Cascino, W. A. Hauser
2010 Neurology  
Objectives: Previous studies that have assessed the risk of developing epilepsy have failed to account for the competing risk of death, significant in the elderly where epilepsy incidence is highest. We report the lifetime risk for epilepsy, accounting for the competing risk of mortality. Methods: Lifetime risk and cumulative incidence of epilepsy were examined among Rochester, MN, residents between 1960 and 1979. Age-, gender-, and calendar year-specific deaths were obtained for Rochester, MN.
more » ... Lifetime risk was calculated as the conditional probability of developing epilepsy by a specific age for a person reaching that age who had not yet developed epilepsy. Lifetime risk and cumulative incidence were compared for age and time period.
doi:10.1212/wnl.0b013e318204a36a pmid:21205691 pmcid:PMC3032191 fatcat:jgewpbaupjegvkwnfotqkcorhi

Incidence and remaining lifetime risk of Parkinson disease in advanced age

J. A. Driver, G. Logroscino, J. M. Gaziano, T. Kurth
2009 Neurology  
Objective: To estimate the incidence and lifetime risk (LTR) of Parkinson disease (PD) in a large cohort of men. Background: Age is the strongest risk factor for PD, but whether its incidence continues to increase after age 80 years remains unclear. Methods: Prospective cohort of 21,970 US male physicians aged 40 -84 years at baseline who did not report PD before study entry. Participants self-reported PD on yearly follow-up questionnaires, and all deaths were confirmed. We calculated incidence
more » ... rates and cumulative incidence using a modified Kaplan-Meier analysis. LTR was estimated by adjusting cumulative incidence for competing risks of death. Results: Five hundred sixty-three cases of PD were identified over 23 years of follow-up. The crude incidence rate of PD was 121 cases/100,000 person-years. Age-specific incidence rates increased sharply beginning at age 60 years, peaked in those aged 85-89 years, and declined beginning at age 90 years. Cumulative incidence substantially overestimated the long-term risk of PD, particularly in those aged 80 years and older. Cumulative incidence was 9.9% (95% confidence interval [CI] 8.48%-11.30%) from ages 45 to 100 years, whereas LTR for the same period was 6.7% (95% CI 6.01%-7.43%). The incidence and LTR of PD decreased with increasing exposure to smoking. Conclusions: Our study provides evidence that the incidence of Parkinson disease (PD) in men increases through age 89 years. Whether the subsequent decline represents a true decrease in risk remains to be established. A history of smoking substantially decreased the incidence and lifetime risk of PD. Incidence studies that do not adjust for competing risks of death may overestimate the true risk of PD in the elderly. Neurology ® 2009;72:432-438 GLOSSARY AD ϭ Alzheimer disease; CI ϭ confidence interval; LTR ϭ lifetime risk; PD ϭ Parkinson disease; PHS ϭ Physicians' Health Study.
doi:10.1212/ pmid:19188574 pmcid:PMC2676726 fatcat:hnbxgleczjfptfsrpc5gxf3bzi

Dietary Iron Intake and Risk of Parkinson's Disease

G. Logroscino, X. Gao, H. Chen, A. Wing, A. Ascherio
2008 American Journal of Epidemiology  
Am J Epidemiol 2008;168:1381-1388 Am J Epidemiol 2008;168:1381-1388 Logroscino et al. Am J Epidemiol 2008;168:1381-1388  ...  Giancarlo Logroscino, Department of Neurology and Psychiatry, School of Medicine, University of Bari, Bari, Italy (e-mail: dentists, osteopaths, optometrists), aged  ... 
doi:10.1093/aje/kwn273 pmid:18945687 pmcid:PMC2727188 fatcat:shk4po2wzrcxdcoa4rlil3t4d4

Coffee Consumption and Risk of Stroke in Women

E. Lopez-Garcia, F. Rodriguez-Artalejo, K. M. Rexrode, G. Logroscino, F. B. Hu, R. M. van Dam
2009 Circulation  
d 404 420 397 372 345 Glycemic load 102 99 96 92 89 Cereal fiber, g/d 3.9 4.1 3.9 3.6 3.3 Whole grains, g/d 17.1 17.4 16.0 14.4 13.0 Fruits, serving/d 0.88 0.94 0.90 0.84  ...  , 25.0 to 27.9, 28.0 to 29.9, Ն30.0 kg/m 2 ); physical activity (Ͻ1.0, 1.0 to 1.9, 2.0 to 3.9, 4.0 to 6.9, Ն7.0 h/wk); alcohol intake (never, 0.1 to 4.9, 5.0 to 9.9, 10.0 to 14.9, 15.0 to 29.9, Ն30.0 g/  ... 
doi:10.1161/circulationaha.108.826164 pmid:19221216 pmcid:PMC2729465 fatcat:aw7lxcmvkrai3icj7tvjwleg3u

Depression and Incident Stroke in Women

A. Pan, O. I. Okereke, Q. Sun, G. Logroscino, J. E. Manson, W. C. Willett, A. Ascherio, F. B. Hu, K. M. Rexrode
2011 Stroke  
mass index (Ͻ23.0, 23.0 -24.9, 25.0 -29.9, 30.0 -34.9, Ն35.0 kg/m 2 ), smoking status (never, past, or current smoking of 1-14, 15-24, or Ն25 cigarettes/d), alcohol intake (0, 0.1-4.9, 5.0 -14.9, Ն15 g/  ...  74.2 Current aspirin use (%) 44.6 45.6 Current multivitamin use (%) 68.6 67.1 Race, white (%) 98.1 97.4 Parental history of myocardial infarction (%) 20.1 18.4 Alcohol consumption, g/  ... 
doi:10.1161/strokeaha.111.617043 pmid:21836097 pmcid:PMC3183155 fatcat:m6jvlquewjbztcjc7r2imaqexi

Bone substitutes in orthopaedic surgery: from basic science to clinical practice

V. Campana, G. Milano, E. Pagano, M. Barba, C. Cicione, G. Salonna, W. Lattanzi, G. Logroscino
2014 Journal of materials science. Materials in medicine  
Bone substitutes are being increasingly used in surgery as over two millions bone grafting procedures are performed worldwide per year. Autografts still represent the gold standard for bone substitution, though the morbidity and the inherent limited availability are the main limitations. Allografts, i.e. banked bone, are osteoconductive and weakly osteoinductive, though there are still concerns about the residual infective risks, costs and donor availability issues. As an alternative, xenograft
more » ... substitutes are cheap, but their use provided contrasting results, so far. Ceramic-based synthetic bone substitutes are alternatively based on hydroxyapatite (HA) and tricalcium phosphates, and are widely used in the clinical practice. Indeed, despite being completely resorbable and weaker than cortical bone, they have exhaustively proved to be effective. Biomimetic HAs are the evolution of traditional HA and contains ions (carbonates, Si, Sr, Fl, Mg) that mimic natural HA (biomimetic HA). Injectable cements represent another evolution, enabling mininvasive techniques. Bone morphogenetic proteins (namely BMP2 and 7) are the only bone inducing growth factors approved for human use in spine surgery and for the treatment of tibial nonunion. Demineralized bone matrix and platelet rich plasma did not prove to be effective and their use as bone substitutes remains controversial. Experimental cell-based approaches are considered the best suitable emerging strategies in several regenerative medicine application, including bone regeneration. In some cases, cells have been used as bioactive vehicles delivering osteoinductive genes locally to achieve bone regeneration. In particular, mesenchymal stem cells have been widely exploited for this purpose, being multipotent cells capable of efficient osteogenic potential. Here we intend to review and
doi:10.1007/s10856-014-5240-2 pmid:24865980 pmcid:PMC4169585 fatcat:v4oarzpxmregzdkgy2rms76n6m

Use of antidepressants and the risk of Parkinson's disease: a prospective study

A Alonso, L A G. Rodriguez, G Logroscino, M A Hernan
2009 Journal of Neurology, Neurosurgery and Psychiatry  
Background-Individuals with depression have a higher risk of Parkinson's disease (PD), but the timing of the association is unknown. We assessed whether initiation of antidepressant therapy was associated with PD risk in a large population-based database from the United Kingdom and explored the timing of this association. Methods-We conducted a case-control study nested in the General Practice Research Database (GPRD) cohort, a large computerized database with clinical information from more
more » ... 3 million individuals in the UK. Cases of PD were identified from the computer records from 1995 to 2001 and matched with up to 10 controls by age, sex and practice. Use of antidepressants was obtained from the computer records. Results-We included 999 PD cases and 6,261 controls. The rate ratio (RR) and 95% confidence interval (CI) of PD in initiators of antidepressant therapy compared with non-initiators was 1.85 (1.25, 2.75). The association was stronger during the first two years after initiation of medication use (RR 2.19; 95% CI 1.38, 3.46) than later (RR 1.23; 95% CI 0.57, 2.67). Results were similar for selective serotonin reuptake inhibitors and tricyclic antidepressants separately. Conclusion-Initiation of any antidepressant therapy was associated with a higher risk of PD in the two years after initiation of treatment, which suggests that depressive symptoms could be an early manifestation of PD, preceding motor dysfunction.
doi:10.1136/jnnp.2008.152983 pmid:19448091 pmcid:PMC2701616 fatcat:cn5ehp35zzadbjubfwfmnopo3u
« Previous Showing results 1 — 15 out of 660 results